
## **Cemal Tamer Erel**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4848286/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum kisspeptin levels along reproductive period in women: is it a marker for aging?. Gynecological Endocrinology, 2022, 38, 267-272.	0.7	4
2	Serum kisspeptin levels correlated with anti-mullerian hormone levels in women with and without polycystic ovarian syndrome. Gynecological Endocrinology, 2021, 37, 462-466.	0.7	5
3	10-year Analysis of Assisted Reproductive Technique Outcomes at a University Hospital. European Archives of Medical Research, 2021, 37, 76-82.	0.0	0
4	Anti-Müllerian hormone and ovarian aging. Gynecological Endocrinology, 2021, 37, 867-868.	0.7	5
5	Predictive factors for the efficacy of Er:YAG laser treatment of urinary incontinence. Maturitas, 2020, 132, 1-6.	1.0	20
6	Should estrogen be used in the co-treatment of COVID-19 patients? What is the rationale?. Maturitas, 2020, 140, 80.	1.0	5
7	Er:YAG laser treatment of urinary incontinence after failed TOT/TVT procedures. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 399-403.	0.5	9
8	Leriche's syndrome and twin pregnancy. Tâ^šÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2020, 17, 63-64.	0.3	0
9	Case report: Vulvodynia treated with Erbium:YAG laser. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 231, 280-281.	0.5	3
10	EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. Maturitas, 2015, 81, 410-413.	1.0	70
11	EMAS position statement: The ten point guide to the integral management of menopausal health. Maturitas, 2015, 81, 88-92.	1.0	76
12	Non-hormonal management of menopausal vasomotor symptoms: Psychosocial interventions. Maturitas, 2015, 82, 444-445.	1.0	0
13	Effects of vitamin K in postmenopausal women: Mini review. Maturitas, 2014, 77, 294-299.	1.0	22
14	EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture. Maturitas, 2014, 78, 131-137.	1.0	6
15	EMAS position statement: Fertility preservation. Maturitas, 2014, 77, 85-89.	1.0	15
16	EMAS position statement: Individualized breast cancer screening versus population-based mammography screening programmes. Maturitas, 2014, 79, 481-486.	1.0	20
17	EMAS position statement: Menopause for medical students. Maturitas, 2014, 78, 67-69.	1.0	7
18	EMAS position statement: Management of uterine fibroids. Maturitas, 2014, 79, 106-116.	1.0	85

CEMAL TAMER EREL

#	Article	IF	CITATIONS
19	EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women. Maturitas, 2013, 74, 279-282.	1.0	33
20	EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women. Maturitas, 2013, 75, 181-190.	1.0	46
21	EMAS position statement: Vitamin D and postmenopausal health. Maturitas, 2012, 71, 83-88.	1.0	95
22	EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis. Maturitas, 2012, 71, 194-198.	1.0	17
23	Is there any correlation between amh and obesity in premenopausal women?. Archives of Gynecology and Obstetrics, 2012, 286, 661-665.	0.8	46
24	EMAS position statement: Bone densitometry screening for osteoporosis. Maturitas, 2011, 68, 98-101.	1.0	17
25	EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas, 2011, 68, 94-97.	1.0	49
26	Erratum to "EMAS position statement: Managing obese postmenopausal women―[Maturitas 66 (2010) 323–326]. Maturitas, 2011, 69, e2.	1.0	0
27	Erratum to "EMAS position statement: Managing the menopause in women with epilepsy―[Maturitas 66 (2010) 327–328]. Maturitas, 2011, 69, e3.	1.0	0
28	Erratum to "EMAS position statement: Bone densitometry screening for osteoporosis―[Maturitas 68 (2011) 98–101]. Maturitas, 2011, 69, e5.	1.0	1
29	Erratum to "EMAS position statement: Managing the menopause in the context of coronary heart disease―[Maturitas 68 (2011) 94–97]. Maturitas, 2011, 69, e6.	1.0	0
30	EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas, 2011, 69, 195-198.	1.0	38
31	EMAS position statement: Managing obese postmenopausal women. Maturitas, 2010, 66, 323-326.	1.0	45
32	EMAS position statement: Managing the menopause in women with epilepsy. Maturitas, 2010, 66, 327-328.	1.0	11
33	The impact of body mass index on assisted reproduction. Current Opinion in Obstetrics and Gynecology, 2009, 21, 228-235.	0.9	77
34	Thin endometrium in assisted reproductive technology. Current Opinion in Obstetrics and Gynecology, 2008, 20, 221-228.	0.9	111
35	Successful pregnancy achieved by assisted reproductive techniques in a woman with severe congenital bicuspid aortic valve stenosis. Archives of Gynecology and Obstetrics, 2007, 275, 299-300.	0.8	3
36	Transobturator tape (TOT) procedure with fluoroscopic guidance: gaining confidence and valuable experience!. Archives of Gynecology and Obstetrics, 2007, 276, 277-279.	0.8	1

CEMAL TAMER EREL

#	Article	IF	CITATIONS
37	Adjusted leptin level (ALL) is a predictor for hyperemesis gravidarum. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 124, 193-196.	0.5	25
38	Difference in αvβ3 integrin expression in endometrial stromal cell in subgroups of women with unexplained infertility. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 126, 206-211.	0.5	25
39	Tibolone and breast cancer. Postgraduate Medical Journal, 2006, 82, 658-662.	0.9	9
40	Is laparoscopy necessary before assisted reproductive technology?. Current Opinion in Obstetrics and Gynecology, 2005, 17, 243-248.	0.9	14
41	High rate of aneuploidy in luteinized granulosa cells obtained from follicular fluid in women who underwent controlled ovarian hyperstimulation. Fertility and Sterility, 2005, 84, 802-804.	0.5	18
42	Serum leptin levels in hypertensive disorder of pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 120, 158-163.	0.5	20
43	Is endometrial apoptosis evidence of endometrial aging in unexplained infertility? a preliminary report. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 121, 195-201.	0.5	8
44	Leptin receptor variant in women with polycystic ovary syndrome. Fertility and Sterility, 2002, 78, 1334-1335.	0.5	8
45	Mammographic density increase in women receiving different hormone replacement regimens. Maturitas, 2001, 40, 151-157.	1.0	35
46	Mammographic Changes in Women Receiving Tibolone Therapy. Fertility and Sterility, 1998, 69, 870-875.	0.5	46
47	Mammographic changes in women on hormonal replacement therapy. Maturitas, 1996, 25, 51-57.	1.0	19
48	DNA ploidy of ectopic pregnancy and first trimester spontaneous abortion investigated by flow cytometry. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 881-885.	1.3	7